ArticleInternational journal of molecular sciences2023
Hypericin-Based Photodynamic Therapy Displays Higher Selectivity and Phototoxicity towards Melanoma and Squamous Cell Cancer Compared to Normal Keratinocytes In Vitro.
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Natural Photosensitizers in Cancer Therapy: A Chemo-Biodiversity Perspective on Light-Activated Natural Compounds.Chemistry & biodiversity · 2026Review
- Hypericin-loaded small extracellular vesicles increase photodynamic therapy and remodel miRNA-mRNA axes in AGS gastric cancer cells.Scientific reports · 2026Article
- DyeDactic workflow to predict halochromism of biosynthetic colourants.Communications chemistry · 2026Article
- Synergistic Combination of Hypericin-Mediated Photodynamic Therapy and HIF-1α siRNA Inhibits Triple-Negative Breast Cancer via Inducing PANoptosis in vitro.Cancer management and research · 2026Article
- Hypericin as a Photodynamic Immunomodulator: A Natural Compound for Dermatological Therapy.Drug design, development and therapy · 2026Review
- Hypericin Photodynamic Therapy Induces Cytotoxicity and Modulates Cytokine Secretion in MCF-7 Breast Cancer Cells.Journal of clinical medicine · 2025Article
- Curcumin-Loaded Nanomaterials as Carriers for Photodynamic Therapy Against Cancers.Gels (Basel, Switzerland) · 2025Review
- Recent advances in phototherapy-based nanomedicine of lymphoma.Materials today. Bio · 2025Review
- Exploring the GSTP1 inhibition potential of photosensitizer compounds for enhanced cancer treatment in photodynamic therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Hypericin-Mediated Photodynamic Therapy for Head and Neck Cancers: A Systematic Review.Biomedicines · 2025Review
- Diverse Therapeutic Potentials of Hypericin: An In-Depth Review.Current topics in medicinal chemistry · 2025Review
- Hypericin Nanoparticles-Associated Photodynamic Therapy Modulates the Biological Behavior of Hepatocellular Carcinoma by SERPINE1.International journal of nanomedicine · 2025Article
- Cytotoxic and Immunomodulatory Effects of Hypericin as a Photosensitizer in Photodynamic Therapy Used on Skin Cell Cultures.Pharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The aim of this study was to explore the potential of hypericin, a naturally occurring photosensi-tizer, for photodynamic therapy (PDT) in skin cancer, investigating its phototoxic effects and mechanisms of action in cancer cells compared to normal skin keratinocytes, squamous cell cancer (SCC-25) cells and melanoma (MUG-Mel2) cells. Hypericin was applied at concentrations ranging from 0.1-40 μM to HaCaT, SCC-25, and MUG-Mel2 cells. After 24 h of incubation, the cells were exposed to orange light at 3.6 J/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.